Catalog No.
DHC85103
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
VH-V-kappa-CH2-CH3
Clonality
Monoclonal
Target
CD37, Tspan-26, TSPAN26, Leukocyte antigen CD37, Tetraspanin-26
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P11049
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
TRU-016, CAS: 1372645-37-8
Clone ID
Otlertuzumab
Otlertuzumab more than a TRU(E) toddler in CLL?, PMID: 24578490
Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review, PMID: 26758269
Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients, PMID: 25146490
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia, PMID: 27977057
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients, PMID: 24927856
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia, PMID: 24381226
Anti-CD37 antibodies for chronic lymphocytic leukemia, PMID: 24555705
Emerging immunological drugs for chronic lymphocytic leukemia, PMID: 26153226
Anti-CD37 targeted immunotherapy of B-Cell malignancies, PMID: 30293139
Novel agents for chronic lymphocytic leukemia, PMID: 23680477
[Chemotherapy-free treatment of chronic lymphocytic leukemia?], PMID: 24085367
Refractory chronic lymphocytic leukemia--new therapeutic strategies, PMID: 21317446
New agents in chronic lymphocytic leukemia, PMID: 20425394
Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art, PMID: 25249370
Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies, PMID: 29323537
Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia, PMID: 23252565
TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies, PMID: 19943209
Gateways to clinical trials, PMID: 20383346
Novel agents for the treatment of chronic lymphocytic leukemia, PMID: 21326166
Action of novel CD37 antibodies on chronic lymphocytic leukemia cells, PMID: 21886169
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals, PMID: 22624718
The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia, PMID: 23667725
Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies, PMID: 23883821
Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies, PMID: 25154027
For research use only. Not for human or drug use.
